eXmoor pharma, a Bristol, UK-based end-to-end cell and gene therapy (CGT) manufacturing partner, raised USD35M in Series A funding.
The round saw participation from Kineticos Ventures and existing investor MVM Partners. In conjunction with the funding, Frank Lis, President and Chief Executive Officer of Kineticos Ventures, is joining eXmoor’s board.
The company intends to use the funds to launch its Cell and Gene Therapy Centre, a 65,000 sq ft GMP manufacturing facility, purpose-built to develop and manufacture autologous and allogeneic cell therapies, as well as viral vectors.
Led by CEO Angela Osborne, eXmoor pharma is a one-stop cell and gene therapy partner accelerating the manufacturing journey from research to patients. Founded in 2004, the company has specialized in the CGT sector since 2007 helping organizations understand, plan and implement the appropriate CMC strategy. The company does this via its translation and capital consulting groups, process and analytical development labs and now GMP manufacturing capability.
eXmoor has completed over 500 projects for 150 organisations, with 80 current employees, with plans to grow to 200 by 2027. The new Cell and Gene Therapy Centre, opening in Bristol in July 2023, will feature a mixture of manufacturing cleanrooms, Process and Analytical Development and QC laboratories, and associated support spaces suitable for all types of CGTs.
FinSMEs
30/05/2023